Bavarian Nordic slumps as it discontinues RSV program

25 July 2023

Shares of Denmark-based vaccine developer Bavarian Nordic (OMX: BAVA) plummeted 21% to 148.80 Danish kroner yesterday, after it announced that its Phase III clinical trial of MVA-BN RSV, a respiratory syncytial virus (RSV) vaccine candidate for adults ≥60 years of age did not meet all the primary endpoints of preventing lower respiratory tract disease (LRTD) from RSV.

The final study results showed that the vaccine candidate had a 59% efficacy in preventing at least two pre-defined LRTD symptoms meeting one of the efficacy criteria of the study. However, when measuring more severe LRTD based on at least three pre-defined symptoms, the vaccine candidate only demonstrated a 42.9% efficacy and missed the co-primary endpoint of the study.

Based on this outcome, Bavarian Nordic will discontinue its RSV program, including its partnership with China’s Nuance Pharma to develop and launch the vaccine for selected Asian markets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK